Diagnostic utility of artificial intelligence software through non-mydriatic digital retinography in the screening of diabetic retinopathy: an overview of reviews.

Objective: To evaluate the capability of artificial intelligence (AI) in screening for diabetic retinopathy (DR) utilizing digital retinography captured by non-mydriatic (NM) ≥45° cameras, focusing on diagnosis accuracy, effectiveness, and clinical safety.

Methods: We performed an overview of systematic reviews (SRs) up to May 2023 in Medline, Embase, CINAHL, and Web of Science. We used AMSTAR-2 tool to assess the reliability of each SR. We reported meta-analysis estimates or ranges of diagnostic performance figures.

Results: Out of 1336 records, ten SRs were selected, most deemed low or critically low quality. Eight primary studies were included in at least five of the ten SRs and 125 in less than five SRs. No SR reported efficacy, effectiveness, or safety outcomes. The sensitivity and specificity for referable DR were 68-100% and 20-100%, respectively, with an AUROC range of 88 to 99%. For detecting DR at any stage, sensitivity was 79-100%, and specificity was 50-100%, with an AUROC range of 93 to 98%.

Conclusions: AI demonstrates strong diagnostic potential for DR screening using NM cameras, with adequate sensitivity but variable specificity. While AI is increasingly integrated into routine practice, this overview highlights significant heterogeneity in AI models and the cameras used. Additionally, our study enlightens the low quality of existing systematic reviews and the significant challenge of integrating the rapidly growing volume of emerging evidence in this field. Policymakers should carefully evaluate AI tools in specific contexts, and future research must generate updated high-quality evidence to optimize their application and improve patient outcomes.